Dulaglutide
Dulaglutide
A once-weekly GLP-1 receptor agonist (Trulicity) approved for type 2 diabetes with cardiovascular benefits. Convenient single-dose pen.
Typical Cost
$800-1000/month (brand)
Status
Research
Peptide Profile
Dulaglutide
Mechanism of Action
Activates GLP-1 receptors to improve glycemic control and reduce appetite. Weekly formulation provides sustained coverage. Cardiovascular benefits demonstrated in REWIND trial.
Common Dosages
subcutaneous
0.75-4.5mg
Weekly · Ongoing
Benefits
Convenient weekly dosing
Good glycemic control
Cardiovascular protection
Moderate weight loss 5-8%
Easy-to-use pen
Side Effects
Nausea
Vomiting
Diarrhea
Constipation
Injection site reactions
Key Research
REWIND trial - Dulaglutide cardiovascular outcomes
Significant reduction in cardiovascular events in type 2 diabetes
Regulatory Status
FDA-approved (Trulicity) for type 2 diabetes. Not specifically approved for weight, though weight loss occurs.
Contraindications
- ⚠Medullary thyroid carcinoma history
- ⚠MEN2 syndrome
- ⚠Pregnancy/breastfeeding
GLP-1 users on dulaglutide benefit from SeraVia formulations for comprehensive metabolic and digestive support.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.